Published in Ann Intern Med on April 18, 2000
The Study of Barrett's Esophagus: What Are the Factors of Progression (BEST) | NCT00586404
Antireflux surgery, barrett esophagus, and adenocarcinoma: there is still room for doubt. Ann Surg (2007) 1.44
Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut (2002) 1.38
Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35
Treatment of ultralong-segment Barrett's using focal and balloon-based radiofrequency ablation. Surg Endosc (2009) 1.20
The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One (2013) 1.08
Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg (2003) 1.08
Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci (2003) 1.05
Spatial structure increases the waiting time for cancer. New J Phys (2011) 1.02
Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus. J Natl Cancer Inst (2003) 0.99
Predictive factors of coexisting cancer in Barrett's high-grade dysplasia. Surg Endosc (2006) 0.96
Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants. PLoS One (2012) 0.94
Natural history of Barrett's esophagus. World J Gastroenterol (2012) 0.93
Antagonist: endoscopic surveillance of patients with Barrett's oesophagus. Gut (2002) 0.89
Economic comparison of current endoscopic practices: Barrett's surveillance vs. ulcerative colitis surveillance vs. biopsy for sprue vs. biopsy for microscopic colitis. Dig Dis Sci (2005) 0.88
Validation of the Prague C & M criteria for the endoscopic grading of Barrett's esophagus by gastroenterology trainees: a multicenter study. Gastrointest Endosc (2012) 0.88
Sex and Gender Differences in Gastroesophageal Reflux Disease. J Neurogastroenterol Motil (2016) 0.87
The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma. Br J Cancer (2011) 0.87
Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma. World J Gastroenterol (2005) 0.85
Pathophysiology and treatment of Barrett's esophagus. World J Gastroenterol (2010) 0.85
Epidermal growth factor receptor expression in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy. Gastroenterol Res Pract (2012) 0.84
Barrett's metaplasia: clinical implications. World J Gastroenterol (2001) 0.84
Endoscopic ablation of Barrett's esophagus using high power setting argon plasma coagulation: a prospective study. World J Gastroenterol (2005) 0.83
Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort. Cancer Epidemiol Biomarkers Prev (2014) 0.82
Multilayered epithelium may be found in patients with Barrett's epithelium and dysplasia or adenocarcinoma. Dig Dis Sci (2006) 0.80
A rational approach to uninvestigated dyspepsia in primary care: review of the literature. Postgrad Med J (2002) 0.78
Diagnosis and management of Barrett's esophagus. Surg Clin North Am (2012) 0.78
Proton Pump Inhibitors: The Culprit for Barrett's Esophagus? Front Oncol (2015) 0.77
Increased expression of VEGF, COX-2, and Ki-67 in Barrett's esophagus: does the length matter? Dig Dis Sci (2011) 0.77
Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nat Commun (2016) 0.77
Magnifying endoscopy for the diagnosis of specialized intestinal metaplasia in short-segment Barrett's esophagus. World J Gastroenterol (2013) 0.76
Gender difference in gastro-esophageal reflux diseases. World J Gastroenterol (2016) 0.76
Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative. United European Gastroenterol J (2016) 0.76
Management of Barrett's oesophagus and intramucosal oesophageal cancer: a review of recent development. Therap Adv Gastroenterol (2012) 0.76
Prevalence of Barrett's esophagus in Northern Greece: A Prospective Study (Barrett's esophagus). Hippokratia (2013) 0.76
Surveillance in Patients With Barrett's Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol (2015) 0.76
MAL hypermethylation is a tissue-specific event that correlates with MAL mRNA expression in esophageal carcinoma. Sci Rep (2013) 0.75
Segment length and risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 0.75
Short-Segment Barrett's Esophagus and Adenocarcinoma. Gastroenterol Hepatol (N Y) (2006) 0.75
Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study. World J Gastrointest Pharmacol Ther (2014) 0.75
Update on management of Barrett's esophagus. World J Gastrointest Pharmacol Ther (2016) 0.75
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
Genetic control of the cell division cycle in yeast. Science (1974) 13.83
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst (1992) 6.18
An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology (1993) 5.41
Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med (1994) 5.37
Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology (1993) 4.41
Long-term survival among men with conservatively treated localized prostate cancer. JAMA (1995) 4.24
Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1997) 4.09
A p53-dependent mouse spindle checkpoint. Science (1995) 4.01
Regulation of mating in the cell cycle of Saccharomyces cerevisiae. J Cell Biol (1977) 3.68
Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol (1988) 3.67
Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1998) 3.66
Pneumatosis intestinalis: a review. Am J Gastroenterol (1995) 3.48
Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet (1999) 3.30
An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res (1998) 3.22
Occupational exposure assessment in case-control studies: opportunities for improvement. Occup Environ Med (2002) 3.21
Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. J Immunol (1986) 3.08
Pregnancy termination in relation to risk of breast cancer. JAMA (1996) 3.04
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol (2000) 2.99
Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med (1999) 2.77
Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol (1995) 2.73
Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol (2000) 2.58
The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol (1996) 2.57
Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology (1992) 2.57
Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology (1994) 2.55
17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A (1996) 2.53
Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. Proc Natl Acad Sci U S A (1987) 2.53
DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology (1992) 2.48
Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology (1985) 2.44
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (1998) 2.43
Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology (1992) 2.35
Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst (1995) 2.24
Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology (1996) 2.23
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med (2001) 2.22
Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol (2001) 2.21
CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood (1990) 2.21
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17
Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology (1987) 2.15
Targeted gene walking polymerase chain reaction. Nucleic Acids Res (1991) 2.14
Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol (1978) 2.13
Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res (2000) 2.13
Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (2001) 2.13
General relative risk functions for case-control studies. Am J Epidemiol (1985) 2.07
Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology (1988) 2.06
p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res (2001) 2.06
Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology (1992) 2.03
Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology (1993) 2.00
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control (2000) 2.00
Cancer surveillance in ulcerative colitis. Gastroenterology (1991) 1.93
Hereditary gastrointestinal polyposis syndromes. Am J Surg Pathol (1986) 1.91
Malignant epithelioid hemangioendothelioma of the liver in young women. Relationship to oral contraceptive use. Am J Surg Pathol (1985) 1.91
Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res (1999) 1.90
Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol (1986) 1.89
An apoptosis-inducing genotoxin differentiates heterozygotic carriers for Werner helicase mutations from wild-type and homozygous mutants. Hum Genet (1997) 1.88
Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest (1989) 1.83
Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1996) 1.82
Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry (1993) 1.77
CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol (1987) 1.76
Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A (1995) 1.75
Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res (1996) 1.74
Gastric cancer. Contemporary aspects. Am J Surg (1977) 1.72
Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum Genet (1999) 1.71
Histologic correlates of gastrointestinal ultrasound images. Gastroenterology (1989) 1.69
Signal transduction through CD4 receptors: stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor. Eur J Immunol (1988) 1.68
p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res (1997) 1.67
Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res (1992) 1.65
A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology (1995) 1.65
Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology (1998) 1.65
Analysis of c-Ki-ras mutations in human colon carcinoma by cell sorting, polymerase chain reaction, and DNA sequencing. Cancer Res (1989) 1.63
Body size and risk of breast cancer. Am J Epidemiol (1997) 1.63
Myoepithelioma of minor salivary gland origin. Light and electron microscopical study. Arch Pathol (1975) 1.63
p53-mutant clones and field effects in Barrett's esophagus. Cancer Res (1999) 1.61
c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology (1990) 1.59